Levodopa challenge test and 123I-metaiodobenzylguanidine scintigraphy for diagnosing Parkinson's disease
Article first published online: 15 FEB 2013
© 2013 John Wiley & Sons A/S
Acta Neurologica Scandinavica
Volume 128, Issue 3, pages 160–165, September 2013
How to Cite
Levodopa challenge test and 123I-metaiodobenzylguanidine scintigraphy for diagnosing Parkinson's disease. Acta Neurol Scand 2013: 128: 160–165. © 2013 John Wiley & Sons A/S., , , , , , , , , , , , , , ,
- Issue published online: 16 AUG 2013
- Article first published online: 15 FEB 2013
- Manuscript Accepted: 11 JAN 2013
- metaiodobenzylguanidine (MIBG) scintigraphy;
- Parkinson's disease
To explore the possibility of a generally applicable tool for the immediate diagnosis of Parkinson's disease (PD) in its early stage, we compared the sensitivity and specificity of an acute levodopa challenge test with that of 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy.
Materials and methods
A consecutive series of 45 patients with extrapyramidal symptoms were recruited to the acute levodopa challenge and evaluated for improvement by use of the Unified Parkinson's Disease Rating Scale motor scores. Of these patients, 32 of them were also examined by MIBG scintigraphy. The patients were followed up for at least 24 months, and 22 patients were diagnosed as having clinically definite PD.
The sensitivity and specificity of the acute levodopa challenge test to predict clinical diagnosis of PD were 81.8% and 81.8%, respectively, which were better than those obtained by MIBG scintigraphy (62.5% and 62.5%). In both early- and middle-stages of PD, the test gave better sensitivity than MIBG scintigraphy.
Considering that the well-established and frequently referred clinical diagnostic criteria require longitudinal observation for at least 24 months, the acute levodopa challenge test can be used as an immediate diagnostic tool for PD with sensitivity and specificity comparable to those of MIBG.